Clindamycin/tretinoin - Verisfield

Drug Profile

Clindamycin/tretinoin - Verisfield

Alternative Names: Tretinoin/clindamycin - Verisfield

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Verisfield
  • Class Antiacnes; Antibacterials; Keratolytics; Lincosamides; Retinoids; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Acne vulgaris

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acne-vulgaris in Greece (Topical, Gel)
  • 14 Nov 2010 Verisfield completes a phase I trial in Acne vulgaris in Greece (EudraCT: 2009-017201-11)
  • 15 Jun 2010 Phase-I clinical trials in Acne vulgaris in Greece (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top